Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Osteoarthritis Pipeline Review, H2 2016: Focus on 56 Companies & 110 Molecules - Research and Markets

Research and Markets
Posted on: 28 Sep 16

Research and Markets has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2016" report to their offering.

'Osteoarthritis - Pipeline Review, H2 2016'; Osteoarthritis pipeline therapeutics constitutes close to 110 molecules. Out of which approximately 98 molecules are developed by Companies and remaining by the Universities Institutes.

Furthermore, the publisher says; Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like nonsteroidal anti-inflammatory drugs (NSAIDs) and exercise.

The report 'Osteoarthritis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 18, 17, 43 and 13 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 6 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Osteoarthritis Overview
  3. Therapeutics Development
  4. Pipeline Products for Osteoarthritis - Overview
  5. Pipeline Products for Osteoarthritis - Comparative Analysis
  6. Osteoarthritis - Therapeutics under Development by Companies
  7. Osteoarthritis - Therapeutics under Investigation by Universities/Institutes
  8. Osteoarthritis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Osteoarthritis - Products under Development by Companies
  13. Osteoarthritis - Products under Investigation by Universities/Institutes
  14. Osteoarthritis - Companies Involved in Therapeutics Development
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AbbVie Inc
  • Abiogen Pharma S.p.A.
  • Ablynx NV
  • Achelios Therapeutics, Inc.
  • Addex Therapeutics Ltd
  • Amgen Inc.
  • Amura Holdings Limited
  • Arcarios BV
  • Asahi Kasei Pharma Corp.
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Cellular Biomedicine Group, Inc.
  • Evgen Pharma Plc
  • Galapagos NV
  • Genequine Biotherapeutics GmbH
  • GlaxoSmithKline Plc
  • IntelliCell BioSciences Inc.
  • Jeil Pharmaceutical Co., Ltd.
  • Levolta Pharmaceuticals, Inc.
  • Medivir AB
  • Merck KGaA
  • Nordic Bioscience A/S
  • Novartis AG
  • Omeros Corporation
  • Ono Pharmaceutical Co., Ltd.
  • OrthoCyte Corporation
  • Osteologix Holdings Plc.
  • Pfizer Inc.
  • Pharmalink AB
  • Philogen S.p.A.
  • STELIS Biopharma Pvt. Ltd.
  • Symic Biomedical, Inc.
  • Takeda Pharmaceutical Company Limited
  • Zimmer Biomet Holdings, Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.